Please use this identifier to cite or link to this item:
http://hdl.handle.net/11434/2037
Title: | A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. |
Epworth Authors: | Prince, Miles |
Other Authors: | Maqbool, M. Gohar Tam, Constantine Morison, Ian Simpson, David Mollee, Peter Schneider, Hans Chan, Henry Juneja, Surrender Harvey, Yasmin Nath, Lakshmi Hissaria, Pravin Wordsworth, Helen Opat, Stephen Talaulikar, Dipti |
Keywords: | Waldenström Macroglobulinaemia (WM) Lymphoplasmacytic Lymphoma IgM Paraprotein Immunoglobulin (Ig) M Monoclonal Gammopathy of undetermined significance (IgM MGUS) Myeloid Differentiation Primary Response 88 (MYD88) C-X-C Motif Chemokine Receptor 4 (CXCR4) Central Nervous System (CNS) Bone Marrow (BM) Paraprotein Differential Diagnosis Follow-Up Study Non-Hodgkin's Lymphoma Epworth Centre for Immunotherapies and Snowdome Laboratories Molecular Oncology and Cancer Immunology Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia |
Issue Date: | Feb-2020 |
Publisher: | Elsevier |
Citation: | Pathology. 2020 Feb;52(2):167-178. |
Abstract: | Waldenström macroglobulinaemia (WM) is an indolent non-Hodgkin lymphoma which usually presents with symptoms related to infiltration of bone marrow or other tissues like lymph nodes, liver or spleen and has certain unusual clinical manifestations, e.g., renal and central nervous system (CNS) involvement. It also has an array of laboratory features including hypersecretion of IgM, cryoglobulinaemia, increased plasma viscosity and identification of mutated MYD88L265P in more than 90% of cases. In this review, we aim to provide a guide to the laboratory investigations recommended for WM at initial diagnosis and at follow-up. A discussion on the nuances of diagnosis and differential diagnoses is followed by bone marrow (BM) assessment, measurement of paraprotein and other ancillary investigations. Recommendations are provided on laboratory work-up at diagnosis, in the asymptomatic follow-up phase, and during and post-treatment. Finally, we briefly discuss the implications of laboratory diagnosis in regard to recruitment and monitoring on clinical trials. |
URI: | http://hdl.handle.net/11434/2037 |
DOI: | 10.1016/j.pathol.2019.11.002 |
PubMed URL: | https://pubmed.ncbi.nlm.nih.gov/31902622 |
ISSN: | 0031-3025 |
Journal Title: | Pathology |
Type: | Journal Article |
Affiliated Organisations: | Department of Haematology, ACT Pathology, Canberra Hospital, ACT, Australia; ANU Medical School, College of Medicine and Health, Australian National University, Canberra, ACT, Australia Peter MacCallum Cancer Center, St Vincent's Hospital and University of Melbourne, Melbourne, Vic, Australia Southern Community Laboratories, Dunedin, New Zealand; Australasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia Department of Haematology, Waitemata District Health Board, Auckland, New Zealand; Medical and Scientific Advisory Group, Myeloma Australia Australasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia; Medical and Scientific Advisory Group, Myeloma Australia; Department of Haematology, Princess Alexandra Hospital and University of Queensland Medical School, Brisbane, Qld, Australia. Australasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia; Alfred Pathology Service and Monash University, Melbourne, Vic, Australia. Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Vic, Australia; Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia; Sullivan Nicolaides Pathology, Brisbane, Qld, Australia Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia; Department of Haematology and Transfusion Medicine, Clinpath Pathology, Adelaide, SA, Australia Australasian Association of Clinical Biochemists (AACB) Monoclonal Gammopathy Working Group (MGWG), Australia; Royal Adelaide Hospital, University of Adelaide and SA Pathology, Adelaide, SA, Australia Medical and Scientific Advisory Group, Myeloma Australia; Epworth Healthcare, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic, Australia Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia; Department of Haematology, Monash Health, Melbourne, Vic, Australia Department of Haematology, ACT Pathology, Canberra Hospital, ACT, Australia; ANU Medical School, College of Medicine and Health, Australian National University, Canberra, ACT, Australia; Medical and Scientific Advisory Group, Myeloma Australia; Pathology Sub-committee of the Lymphoma and Related Diseases Registry (LaRDR), Australia |
Type of Clinical Study or Trial: | Clinical Trial |
Appears in Collections: | Cancer Services MOCI |
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.